This is a preview of subscription content, log in via an institution to check access.
Reference
Norgine. PBAC Approves XIFAXAN (Rifaxamin a) 550 mg Cost Effectiveness in Australia. Media Release : 24 May 2013. Available from: URL: http://www.norgine.com
Rights and permissions
About this article
Cite this article
Rifaxamin recommended by Australian PBAC. PharmacoEcon Outcomes News 680, 15 (2013). https://doi.org/10.1007/s40274-013-0493-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0493-4